Rockefeller Capital Management
LXEO icon

Rockefeller Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Rockefeller Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.55K Buy
1,141
+441
+63% +$3.13K ﹤0.01% 4158
2025
Q4 		$6.95K Buy
700
+500
+250% +$4.56K ﹤0.01% 3952
2025
Q3 		$1.33K Buy
+200
New +$967 ﹤0.01% 4146

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's LXEO Position: Q1 2026 in Review

Rockefeller Capital Management increased its Lexeo Therapeutics (LXEO) stake by 63% in Q1 2026, buying an estimated $3.13K and bringing the position to 1,141 shares worth $6.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4158.

Rockefeller Capital Management first reported a position in LXEO in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.95K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Rockefeller Capital Management held 1,141 shares of Lexeo Therapeutics worth $6.55K as of Q1 2026.
  • Rockefeller Capital Management bought 441 Lexeo Therapeutics shares in Q1 2026, an estimated $3.13K.
  • Lexeo Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4158 holding.
  • Rockefeller Capital Management first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Lexeo Therapeutics position peaked at $6.95K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.